The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B
- PMID: 8087845
- DOI: 10.1016/s0092-8674(94)90482-0
The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B
Abstract
We demonstrate an essential role for the proteasome complex in two proteolytic processes required for activation of the transcription factor NF-kappa B. The p105 precursor of the p50 subunit of NF-kappa B is processed in vitro by an ATP-dependent process that requires proteasomes and ubiquitin conjugation. The C-terminal region of p105 is rapidly degraded, leaving the N-terminal p50 domain. p105 processing can be blocked in intact cells with inhibitors of the proteasome or in yeast with proteasome mutants. These inhibitors also block the activation of NF-kappa B and the rapid degradation of I kappa B alpha induced by tumor necrosis factor alpha. Thus, the ubiquitin-proteasome pathway functions not only in the complete degradation of polypeptides, but also in the regulated processing of precursors into active proteins.
Similar articles
-
Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway.Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10599-603. doi: 10.1073/pnas.92.23.10599. Proc Natl Acad Sci U S A. 1995. PMID: 7479848 Free PMC article.
-
NF-kappa B p105 processing via the ubiquitin-proteasome pathway.J Biol Chem. 1998 Jan 16;273(3):1409-19. doi: 10.1074/jbc.273.3.1409. J Biol Chem. 1998. PMID: 9430676
-
Cyclosporin A interferes with the inducible degradation of NF-kappa B inhibitors, but not with the processing of p105/NF-kappa B1 in T cells.Eur J Immunol. 1997 Jul;27(7):1601-9. doi: 10.1002/eji.1830270703. Eur J Immunol. 1997. PMID: 9247567
-
Regulatory functions of ubiquitination in the immune system.Nat Immunol. 2002 Jan;3(1):20-6. doi: 10.1038/ni0102-20. Nat Immunol. 2002. PMID: 11753406 Review.
-
Control of IkappaBalpha proteolysis by the ubiquitin-proteasome pathway.Biochimie. 2001 Mar-Apr;83(3-4):351-6. doi: 10.1016/s0300-9084(01)01237-8. Biochimie. 2001. PMID: 11295496 Review.
Cited by
-
ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.Neoplasia. 2013 Jun;15(6):649-59. doi: 10.1593/neo.121896. Neoplasia. 2013. PMID: 23730213 Free PMC article.
-
Inhibition of immunoproteasome reduces infarction volume and attenuates inflammatory reaction in a rat model of ischemic stroke.Cell Death Dis. 2015 Jan 29;6(1):e1626. doi: 10.1038/cddis.2014.586. Cell Death Dis. 2015. PMID: 25633295 Free PMC article.
-
hRpn13 shapes the proteome and transcriptome through epigenetic factors HDAC8, PADI4, and transcription factor NF-κB p50.Mol Cell. 2024 Feb 1;84(3):522-537.e8. doi: 10.1016/j.molcel.2023.11.035. Epub 2023 Dec 26. Mol Cell. 2024. PMID: 38151017 Free PMC article.
-
NF-κB, the first quarter-century: remarkable progress and outstanding questions.Genes Dev. 2012 Feb 1;26(3):203-34. doi: 10.1101/gad.183434.111. Genes Dev. 2012. PMID: 22302935 Free PMC article. Review.
-
Riboflavin in Neurological Diseases: A Narrative Review.Clin Drug Investig. 2021 Jun;41(6):513-527. doi: 10.1007/s40261-021-01038-1. Epub 2021 Apr 22. Clin Drug Investig. 2021. PMID: 33886098 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials